S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
LON:IMM

ImmuPharma (IMM) Share Price, News & Analysis

GBX 2.12
-0.06 (-2.52%)
(As of 03/28/2024 07:40 PM ET)
Today's Range
2.05
2.37
50-Day Range
0.85
2.50
52-Week Range
0.82
3.80
Volume
2.37 million shs
Average Volume
2.69 million shs
Market Capitalization
£8.85 million
P/E Ratio
N/A
Dividend Yield
0.77%
Price Target
N/A
IMM stock logo

About ImmuPharma Stock (LON:IMM)

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

IMM Stock Price History

IMM Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
ImmuPharma PLC IMM
ImmuPharma PLC (25I.SG)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
ImmuPharma shares jump 6.5% after FDA update
ImmuPharama eyes clinical trial progress
ImmuPharma eyes clinical trial progress
ImmuPharma "looking forward" to upcoming FDA meetings
ImmuPharma partner gets FDA meeting date
ImmuPharma rises 4% after it reveals headway with lead asset
See More Headlines
Receive IMM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/30/2020
Today
3/28/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
£-2,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£94,819.00
Cash Flow
GBX 0.10 per share

Miscellaneous

Free Float
N/A
Market Cap
£8.85 million
Optionable
Not Optionable
Beta
1.32
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Timothy Paul McCarthy XIV (Age 68)
    FCCA, M.B.A., MBA, Chairman & CEO
    Comp: $106.5k
  • Dr. Timothy Gary Franklin M.B.A. (Age 60)
    Ph.D., COO & Director
    Comp: $92.5k
  • Ms. Lisa Baderoon (Age 58)
    Head of Investor Relations & Non Executive Director
    Comp: $48k
  • Dr. Jean-Marie Geiger PharmD
    MD, Head of Clinical Development
  • Dr. Laura Mauran-Ambrosino
    Chief Scientific Officer of ImmuPharma Biotech
  • Ms. Lara E. Sucheston-Campbell
    Head of Clinical & Medical Affairs
  • Dr. Sébastien R. Goudreau Ph.D. (Age 43)
    CEO of ImmuPharma Biotec & Director

IMM Stock Analysis - Frequently Asked Questions

How have IMM shares performed in 2024?

ImmuPharma's stock was trading at GBX 1.67 at the beginning of 2024. Since then, IMM stock has increased by 27.4% and is now trading at GBX 2.13.
View the best growth stocks for 2024 here
.

How were ImmuPharma's earnings last quarter?

ImmuPharma plc (LON:IMM) announced its earnings results on Wednesday, September, 30th. The company reported ($1.69) EPS for the quarter.

What other stocks do shareholders of ImmuPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuPharma investors own include Castleton Technology (CTP), MOTIF BIO PLC/S (MTFB), Aminex (AEX), Legendary Investments (LEG), Richland Resources Ltd (RLD.L) (RLD), Sound Energy (SOU), Thor Energy (THR), Acacia Mining (ACA), ALU (ALU) and (DARA) (DARA).

How do I buy shares of ImmuPharma?

Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:IMM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners